


RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1643

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX0499US.NP
Inventors: Fan et al.
Serial No.: 10/593,799
Filing Date: August 6, 2007
Examiner: Blanchard, David J.
Customer No.: 32800
Group Art Unit: 1643
Confirmation No.: 2565
Title: LNG105 Antibody Composition and Methods
of Use, and Use of LNG105 to Assess Lung
Cancer Risk

Electronically Submitted via EFS-Web
Date: September 7, 2010

I hereby certify that this paper is being electronically
submitted on the date indicated above to the
Commissioner for Patents, U.S. Patent &
Trademark Office.

By 
Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

Commissioner for Patents
U.S. Patent & Trademark Office

Dear Sir:

Reply under 37 C.F.R. 1.116

This is a reply to the Final Rejection mailed September 4,
2010 setting a three (3) month statutory period for response.
Please enter the following amendments and remarks into the
record.

Amendments to the claims are reflected in the listing of
claims which begins on page 2 of this paper.

Remarks begin on page 6.